Francesco BertoliniVisnu LohsiriwatJean Yves PetitMikhail G. KoloninIstituto Europeo di OncologiaMahidol UniversityUniversity of Texas Health Science Center at Houston2018-06-112018-06-112012-08-01Biochimica et Biophysica Acta - Reviews on Cancer. Vol.1826, No.1 (2012), 209-214187925610304419X2-s2.0-84860588514https://repository.li.mahidol.ac.th/handle/20.500.14594/13651Despite recent evidence of the cancer-promoting role of adipose tissue-derived progenitor and differentiated cells, the use of lipotransfer for tissue/organ reconstruction after surgical removal of cancer is increasing worldwide. Here we discuss in a multidisciplinary fashion the preclinical data connecting obesity, adipose cells and cancer progression, as well as the clinical data concerning safety of lipotransfer procedures in cancer patients. A roadmap towards a more rationale use of lipotransfer in oncology is urgently needed and should include preclinical studies to dissect the roles of different adipose tissue-derived cells, the evaluation of drugs currently candidate to inhibit the interaction between adipose and tumor cells, and carefully designed clinical trials to investigate the safety of lipotransfer procedures in cancer patients. © 2012 Elsevier B.V.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineReviewSCOPUS10.1016/j.bbcan.2012.04.004